Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88

Benzinga · 2d ago
Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $82 to $88.